[ad_1] Deucravacitinib Shows Durable Efficacy in Psoriasis Over 2 Years, finds study We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok [ad_2] Source link
[ad_1] Alumis is preparing to file its oral TYK2 inhibitor envudeucitinib as a treatment for psoriasis later this year, after a pair of positive phase 3 trials. The South San Francisco biotech said envudeucitinib (formerly ESK-001) delivered “leading skin clearance” in the phase 3 ONWARD1 and ONWARD2 trials, meeting all primary and secondary endpoints with…
[ad_1] Dietary Supplements Safe and Promising Adjunctive Therapy for Psoriasis, Suggests Study We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok [ad_2] Source link
[ad_1] Antibiotic Use May Reduce Biologic Treatment Persistence in Psoriasis: JAMA We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok [ad_2] Source link
[ad_1] Medical Bulletin 27/December/2025 We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok [ad_2] Source link
[ad_1] Inflammatory Bowel Disease and BMI Increase Risk of Hidradenitis Suppurativa: JAMA We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok [ad_2] Source link
[ad_1] More than eight million people in the United States have psoriasis, which most commonly causes itchy, scaly patches of thick, red, dry skin called plaques. [1] While there are signs and symptoms that set the disease apart from other conditions affecting the skin, it isn’t always easy to distinguish it at first. Because psoriasis…
[ad_1] Armed with positive results in two phase 3 trials, Takeda intends to file for approval of its oral psoriasis therapy zasocitinib in the US and other countries next year, with Bristol Myers Squibb’s Sotyktu in its sights. Once-daily zasocitinib, described as a second-generation TYK2 inhibitor, met all its safety and efficacy objectives in patients…
[ad_1] Potential biomarker for targeted psoriasis therapy discovered We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok [ad_2] Source link
[ad_1] Psoriasis linked to Risk of Diabetic Retinopathy in Type-2 Diabetes Mellitus Patients: Study We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok [ad_2] Source link